Relypsa Submits Supplemental New Drug Application to FDA Requesting Label Changes for Veltassa Based on Phase 1 Drug-Drug Interaction Studies

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/13/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. TSLA

Go back to Relypsa Submits Supplemental New Drug Application to FDA Requesting Label Changes for Veltassa Based on Phase 1 Drug-Drug Interaction Studies

BTIG Remains Bullish on Relypsa (RLYP) Following 'Surprise' CRL for AstaZeneca's (AZN) ZS-9

May 27, 2016 8:50 AM EDT

BTIG is joining in on the slew of analyst coverage for Relypsa (Nasdaq: RLYP) today.

Analyst Timothy Chiang commented today: This morning, AstraZeneca (NYSE: AZN) announced that it had received a... More